Diphenyl difluoroketone: A potent chemotherapy candidate for human hepatocellular carcinoma

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Liang, Yingjian ^a   Yin, Dalong ^a   Hou, Limin ^a   Zheng, Tongsen ^a   Wang, Jiabei ^a   Meng, Xianzhi ^a   Lu, Zhaoyang ^a   Song, Xuan ^a   Pan, Shangha ^a   Jiang, Hongchi ^a   Liu, Lianxin ^a  

^a THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 9; CYCLIN B1; CYCLIN DEPENDENT KINASE 1; CYCLINE; CYCLOOXYGENASE 2; DIPHENYL DIFLUOROKETONE; EF 24; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; PROTEIN BCL 2; SYNAPTOTAGMIN I; UNCLASSIFIED DRUG; 3,5 BIS(2 FLUOROBENZYLIDENE)PIPERIDIN 4 ONE; 3,5-BIS(2-FLUOROBENZYLIDENE)PIPERIDIN-4-ONE; BENZYLIDENE DERIVATIVE; PIPERIDONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BCL 2 GENE; BODY WEIGHT; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL NUCLEUS; CELL STRAIN HEP3B; CELL STRAIN HEPG2; CELL STRAIN HUH 7; CELL STRAIN PLC PRF 5; CELL STRAIN SK HEP 1; CHROMATIN CONDENSATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; COX 2 GENE; CYCLIN B1 GENE; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; ENZYME ACTIVATION; FLOW CYTOMETRY; GENE; LIVER CELL CARCINOMA; LIVER WEIGHT; MITOSIS INHIBITION; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; SPLEEN WEIGHT; TUMOR XENOGRAFT; ANIMAL; CELL CYCLE; CELL PROLIFERATION; DRUG EFFECT; DRUG SCREENING; HUMAN; LIVER TUMOR; METABOLISM; NUDE MOUSE; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; BENZYLIDENE COMPOUNDS; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN B1; CYCLOOXYGENASE 2; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MICE; MICE, NUDE; NF-KAPPA B; PIPERIDONES; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80052042048     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0023908     Document Type: Article

References (40)

1. Hussain SA, Ferry DR, El-Gazzaz G, Mirza DF, James ND, et al. (2001) Hepatocellular carcinoma. Ann Oncol 12: 161-172.
2. Yang TS, Wang CH, Hsieh RK, Chen JS, Fung MC, (2002) Gemcitabine and doxorubicin for the treatment of patients with advanced hepatocellular carcinoma: a phase I-II trial. Ann Oncol 13: 1771-1778.
3. Celton-Morizur S, Desdouets C, (2010) Polyploidization of liver cells. Adv Exp Med Biol 676: 123-135.
4. Nagano H, (2010) Treatment of advanced hepatocellular carcinoma: intraarterial infusion chemotherapy combined with interferon. Oncology 78 (Suppl 1): 142-147.
5. Lencioni R, (2010) Loco-regional treatment of hepatocellular carcinoma in the era of molecular targeted therapies. Oncology 78 (Suppl 1): 107-112.
6. Ikeda K, (2010) [Current therapy for hepatocellular carcinoma]. Nippon Rinsho 68: 1129-1136.
7. Toso C, Mentha G, Kneteman NM, Majno P, (2010) The place of downstaging for hepatocellular carcinoma. J Hepatol 52: 930-936.
8. Dusheiko GM, Hobbs KE, Dick R, Burroughs AK, (1992) Treatment of small hepatocellular carcinomas. Lancet 340: 285-288.
9. Bruix J, (1997) Treatment of hepatocellular carcinoma. Hepatology 25: 259-262.
10. Venook AP, (1994) Treatment of hepatocellular carcinoma: too many options? J Clin Oncol 12: 1323-1334.
11. Makuuchi M, Kosuge T, Takayama T, Yamazaki S, Kakazu T, et al. (1993) Surgery for small liver cancers. Semin Surg Oncol 9: 298-304.
12. Guha S, Eibl G, Kisfalvi K, Fan RS, Burdick M, et al. (2005) Broad-spectrum G protein-coupled receptor antagonist, [D-Arg1,D-Trp5,7,9,Leu11]SP: a dual inhibitor of growth and angiogenesis in pancreatic cancer. Cancer Res 65: 2738-2745.
13. (1995) A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. N Engl J Med 332: 1256-1261.
14. Siegel AB, Olsen SK, Magun A, Brown RS Jr, (2010) Sorafenib: where do we go from here? Hepatology 52: 360-369.
15. Nakajima A, Yamamoto Y, Taura K, Hata K, Fukumoto M, et al. (2004) Beneficial effect of cepharanthine on overcoming drug-resistance of hepatocellular carcinoma. Int J Oncol 24: 635-645.
16. Pastorelli D, Cartei G, Zustovich F, Marchese F, Artioli G, et al. (2006) Gemcitabine and liposomal doxorubicin in biliary and hepatic carcinoma (HCC) chemotherapy: preliminary results and review of the literature. Ann Oncol 17 (Suppl 5): v153-157.
17. Anand P, Sundaram C, Jhurani S, Kunnumakkara AB, Aggarwal BB, (2008) Curcumin and cancer: an "old-age" disease with an "age-old" solution. Cancer Lett 267: 133-164.
18. Labbozzetta M, Notarbartolo M, Poma P, Giannitrapani L, Cervello M, et al. (2006) Significance of autologous interleukin-6 production in the HA22T/VGH cell model of hepatocellular carcinoma. Ann N Y Acad Sci 1089: 268-275.
19. Bae MK, Kim SH, Jeong JW, Lee YM, Kim HS, et al. (2006) Curcumin inhibits hypoxia-induced angiogenesis via down-regulation of HIF-1. Oncol Rep 15: 1557-1562.
20. Choi H, Chun YS, Kim SW, Kim MS, Park JW, (2006) Curcumin inhibits hypoxia-inducible factor-1 by degrading aryl hydrocarbon receptor nuclear translocator: a mechanism of tumor growth inhibition. Mol Pharmacol 70: 1664-1671.
21. Cao J, Liu Y, Jia L, Zhou HM, Kong Y, et al. (2007) Curcumin induces apoptosis through mitochondrial hyperpolarization and mtDNA damage in human hepatoma G2 cells. Free Radic Biol Med 43: 968-975.
22. Aggarwal BB, Kumar A, Bharti AC, (2003) Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 23: 363-398.
23. Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, et al. (1998) Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med 64: 353-356.
24. Sun A, Shoji M, Lu YJ, Liotta DC, Snyder JP, (2006) Synthesis of EF24-tripeptide chloromethyl ketone: a novel curcumin-related anticancer drug delivery system. J Med Chem 49: 3153-3158.
25. Thomas SL, Zhong D, Zhou W, Malik S, Liotta D, et al. (2008) EF24, a novel curcumin analog, disrupts the microtubule cytoskeleton and inhibits HIF-1. Cell Cycle 7: 2409-2417.
26. Subramaniam D, May R, Sureban SM, Lee KB, George R, et al. (2008) Diphenyl difluoroketone: a curcumin derivative with potent in vivo anticancer activity. Cancer Res 68: 1962-1969.
27. Thomas SL, Zhao J, Li Z, Lou B, Du Y, et al. (2010) Activation of the p38 pathway by a novel monoketone curcumin analog, EF24, suggests a potential combination strategy. Biochem Pharmacol 80: 1309-1316.
28. Adams BK, Cai J, Armstrong J, Herold M, Lu YJ, et al. (2005) EF24, a novel synthetic curcumin analog, induces apoptosis in cancer cells via a redox-dependent mechanism. Anticancer Drugs 16: 263-275.
29. Mosley CA, Liotta DC, Snyder JP, (2007) Highly active anticancer curcumin analogues. Adv Exp Med Biol 595: 77-103.
30. Kasinski AL, Du Y, Thomas SL, Zhao J, Sun SY, et al. (2008) Inhibition of IkappaB kinase-nuclear factor-kappaB signaling pathway by 3,5-bis(2-flurobenzylidene)piperidin-4-one (EF24), a novel monoketone analog of curcumin. Mol Pharmacol 74: 654-661.
31. Kawakami H, Tomita M, Matsuda T, Ohta T, Tanaka Y, et al. (2005) Transcriptional activation of survivin through the NF-kappaB pathway by human T-cell leukemia virus type I tax. Int J Cancer 115: 967-974.
32. Catz SD, Johnson JL, (2001) Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostate cancer. Oncogene 20: 7342-7351.
33. Khoshnan A, Tindell C, Laux I, Bae D, Bennett B, et al. (2000) The NF-kappa B cascade is important in Bcl-xL expression and for the anti-apoptotic effects of the CD28 receptor in primary human CD4+ lymphocytes. J Immunol 165: 1743-1754.
34. Chu ZL, McKinsey TA, Liu L, Gentry JJ, Malim MH, et al. (1997) Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kappaB control. Proc Natl Acad Sci U S A 94: 10057-10062.
35. Selvendiran K, Tong L, Vishwanath S, Bratasz A, Trigg NJ, et al. (2007) EF24 induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by increasing PTEN expression. J Biol Chem 282: 28609-28618.
36. Cao J, Jia L, Zhou HM, Liu Y, Zhong LF, (2006) Mitochondrial and nuclear DNA damage induced by curcumin in human hepatoma G2 cells. Toxicol Sci 91: 476-483.
37. Yuan S, Zhang X, Lu L, Xu C, Yang W, et al. (2004) Anticancer activity of methoxymorpholinyl doxorubicin (PNU 152243) on human hepatocellular carcinoma. Anticancer Drugs 15: 641-646.
38. Karin M, (2009) NF-kappaB as a critical link between inflammation and cancer. Cold Spring Harb Perspect Biol 1: a000141.
39. Antoon JW, White MD, Slaughter EM, Davis JL, Khalili HS, et al. (2011) Targeting NF-kB mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2. Cancer Biol Ther 11.
40. Adams BK, Ferstl EM, Davis MC, Herold M, Kurtkaya S, et al. (2004) Synthesis and biological evaluation of novel curcumin analogs as anti-cancer and anti-angiogenesis agents. Bioorg Med Chem 12: 3871-3883.